BIOVIE INC.
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 06/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $8.6M | $8.8M | $11.6M | $9.8M | $4.6M |
| Research and development | $9.3M | $23.1M | $33.3M | $17.3M | $2.5M |
| Operating expenses | $18.1M | $32.2M | $45.1M | $27.3M | $138.1M |
| Operating income | -$18.1M | -$32.2M | -$45.1M | -$27.3M | -$138.1M |
| Interest expense | $332,720 | $2.9M | $4.3M | $2.2M | $559,455 |
| Net income | -$17.5M | -$32.1M | -$50.3M | -$26.1M | -$130.2M |
| Balance Sheet | |||||
| Cash and equivalents | $17.5M | $23.8M | $19.5M | $18.6M | — |
| Current assets | $20.7M | $24.0M | $34.0M | $18.8M | $4.6M |
| Total assets | $21.6M | $25.2M | $35.1M | $20.1M | $6.0M |
| Current liabilities | $2.3M | $9.4M | $14.5M | $4.2M | $996,374 |
| Total liabilities | $2.6M | $9.7M | $19.8M | $16.4M | $996,374 |
| Stockholders' equity | $19.0M | $15.5M | $15.3M | $3.7M | $5.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$19.0M | -$27.9M | -$40.3M | -$19.0M | -$10.5M |
| Stock-based compensation | $1.2M | $2.8M | $4.2M | $5.8M | $3.0M |
Shares outstanding 7.5M · Free float 99.1%
Annual filing data through FY ended June 30, 2025; float as of July 14, 2026.